71![DOCUMENT INFORMATION PAGE DOCUMENT INFORMATION PAGE](https://www.pdfsearch.io/img/e018bed1fabb6552877c511f3ea05899.jpg) | Add to Reading ListSource URL: www.accessdata.fda.govLanguage: English - Date: 2009-03-31 16:05:30
|
---|
72![](https://www.pdfsearch.io/img/b7ffd5f8bd267715aa5bb4d97caf1526.jpg) | Add to Reading ListSource URL: www.accessdata.fda.govLanguage: English - Date: 2011-01-05 14:23:33
|
---|
73![1 2 3 MEDICATION GUIDE ADVAIR HFA [ad′ vair[removed]Inhalation Aerosol 1 2 3 MEDICATION GUIDE ADVAIR HFA [ad′ vair[removed]Inhalation Aerosol](https://www.pdfsearch.io/img/863bb86b0f22b250a1feb0ef5dec5084.jpg) | Add to Reading ListSource URL: www.accessdata.fda.govLanguage: English - Date: 2011-01-05 14:23:33
|
---|
74![DIVISION OF BIOEQUIVALENCE REVIEW DIVISION OF BIOEQUIVALENCE REVIEW](https://www.pdfsearch.io/img/2765ec5928eed29b4ff355d5deaac327.jpg) | Add to Reading ListSource URL: www.fda.govLanguage: English |
---|
75![DOCUMENT INFORMATION PAGE DOCUMENT INFORMATION PAGE](https://www.pdfsearch.io/img/bac457b717152b2373acf7214770274c.jpg) | Add to Reading ListSource URL: www.accessdata.fda.govLanguage: English - Date: 2009-03-31 16:06:05
|
---|
76![IMPORTANT REVISIONS TO PRESCRIBING INFORMATION FOR SEREVENT® (salmeterol xinafoate) AND ADVAIR DISKUS® (fluticasone propionate and salmeterol inhalation powder) GlaxoSmithKline PO Box 13398 IMPORTANT REVISIONS TO PRESCRIBING INFORMATION FOR SEREVENT® (salmeterol xinafoate) AND ADVAIR DISKUS® (fluticasone propionate and salmeterol inhalation powder) GlaxoSmithKline PO Box 13398](https://www.pdfsearch.io/img/69bbab10987600512c1888b27ff62e6e.jpg) | Add to Reading ListSource URL: www.fda.govLanguage: English |
---|
77![[removed]Federal Register / Vol. 68, No[removed]Tuesday, July 8, [removed]Notices TABLE 1.—ESTIMATED ANNUAL REPORTING BURDEN 1—Continued Item [removed]Federal Register / Vol. 68, No[removed]Tuesday, July 8, [removed]Notices TABLE 1.—ESTIMATED ANNUAL REPORTING BURDEN 1—Continued Item](https://www.pdfsearch.io/img/7627e2a32b1b66fc30ae1457571d22a9.jpg) | Add to Reading ListSource URL: www.fda.govLanguage: English |
---|
78![FLUTICASONE PROPIONATE OINTMENT, 0.005% For Dermatologic Use Only Not for Ophthalmic Use DESCRIPTION: FLUTICASONE PROPIONATE OINTMENT, 0.005% For Dermatologic Use Only Not for Ophthalmic Use DESCRIPTION:](https://www.pdfsearch.io/img/374bbe0e9e264f7781f1fb654565b7db.jpg) | Add to Reading ListSource URL: www.fougera.comLanguage: English - Date: 2009-11-24 10:11:58
|
---|
79![® FLUTICASONE PROPIONATE CREAM, 0.05% FOR DERMATOLOGIC USE ONLY NOT FOR OPHTHALMIC USE ® FLUTICASONE PROPIONATE CREAM, 0.05% FOR DERMATOLOGIC USE ONLY NOT FOR OPHTHALMIC USE](https://www.pdfsearch.io/img/ff027594441beb3a7198a6acbbe0e2dc.jpg) | Add to Reading ListSource URL: www.fougera.comLanguage: English - Date: 2012-06-26 14:51:37
|
---|
80![Summary Basis of Decision Avamys Summary Basis of Decision Avamys](https://www.pdfsearch.io/img/826d0fb99ab4318091b62b1c8cdaf814.jpg) | Add to Reading ListSource URL: www.hc-sc.gc.caLanguage: English - Date: 2013-07-12 14:26:37
|
---|